Debrecen

• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended
  2023-504944-32-00 4 2021-02-17 Non-clear Cell Renal Cell Carcinoma
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi … Ended
  2024-516691-14-00 7 2021-01-05 B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocy
• A study to test the efficacy and safety of Lazertinib in the treatment of patients with Locally Advanced or Metastatic Non-Small Cell Lung C … Ended
  2024-514771-18-00 5 2020-12-15 Adenocarcinoma of the lung (non-small cell lung cancer); locally advan
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended
  2023-506527-28-00 5 2020-06-29 Axial Spondyloarthritis
• Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended
  2023-507221-42-00 5 2020-06-03 Acute Myeloid Leukemia in First Remission
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Ended
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended
  2023-506528-95-00 5 2019-11-21 Psoriatic Arthritis
• A study to learn about the effects and safety of obeticholic acid in combination with bezafibrate in participants with primary biliary chola … Ended
  2024-513762-18-00 4 2019-09-20 Primary Biliary Cholangitis (PBC)
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Ended
  2023-504928-26-00 5 2019-07-19 Chronic Migraine
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended
  2023-509296-16-00 4 2019-06-17 Moderate to severe hidradenitis suppurativa
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC

Showing 481–504 of 524 trials